Noteworthy studies presented at the 3rd European Lung Cancer Conference

April 11th, 2012
Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.

Three studies have been indicated as noteworthy:

Abstract 164O

First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 166O

Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 77O

Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer

Proffered Paper session, Friday, April 20, 14:30-16:00, Room C

Provided by European Society for Medical Oncology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Jawbone files lawsuit against rival Fitbit

In a clash of rival makers of fitness trackers, Jawbone is suing Fitbit and a group of employees who quit Jawbone to work for Fitbit, saying they stole trade secrets, business plans, market research, and other information.

Slow start, gradual improvement for US Internet gambling

Internet gambling is off to a slow start in the United States, with banks hesitant to handle credit card payments for online bets and some politicians and casino moguls pushing to ban it, but there remains potential for great ...